Botanix Pharmaceuticals
  • Home
  • About
  • Technology
  • Pipeline
  • Sofpironium Bromide
  • Clinical Trials
  • Invest
  • News
  • Contact
  • Search
  • Menu Menu
  • Facebook
  • LinkedIn
  • Twitter
  • Youtube
News

Botanix Pharmaceuticals (ASX:BOT) launches Phase 2 BTX 1801 study for SSIs

March 13, 2020/in Latest News /by administrator
Source:
The Market Herald
https://themarketherald.com.au/botanix-pharmaceuticals-asxbot-launches-phase-2-btx-1801-study-for-ssis-2020-03-13

/wp-content/uploads/botanix-logo.png 0 0 administrator /wp-content/uploads/botanix-logo.png administrator2020-03-13 10:18:082020-07-07 11:06:49Botanix Pharmaceuticals (ASX:BOT) launches Phase 2 BTX 1801 study for SSIs

Categories

  • ASX Releases
  • Featured
  • Journal Articles
  • Latest News
  • News
  • Presentations
  • Videos

Social

Facebook
LinkedIn
Twitter
Youtube

Where to find us

AUSTRALIA

Level 1, 50 Angove Street, North Perth WA 6006

USA

3602 Horizon Drive, Suite 160, King of Prussia, PA 19406

Subscribe

Be notified of important news from Botanix.

Subscribe

Contact us

AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com

© Copyright - Botanix Pharmaceuticals
  • Legal notice
Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX... Botanix reshuffles business priorities
Scroll to top